Pfizer Animal Health has launched a dedicated equine business unit to provide a higher level of service and a comprehensive range of products to equine vets across the UK.
Pfizer Animal Health has launched a dedicated Equine Business Unit to provide a higher level of service and a comprehensive range of products to equine vets across the UK.
Created following the merger with Fort Dodge, the Pfizer Equine Business Unit is headed by Ben Lacey, who has previously held both technical and sales roles at Pfizer. Mr Lacey and his team have a brief to offer a breadth of product, support and flexibility not previously available to equine vets.
The product range offered by the Pfizer Equine Business Unit includes:
- The Equest range of parasiticides;
- Duvaxyn vaccines for equine herpes virus, West Nile virus and rotavirus;
- Equimidine; and
Also offered are existing Pfizer brands such as:
- The Equip vaccine range,
- The antibiotic Excenel sterile powder,
- NSAID Rimadyl for horses; and
- Depo-Medrone V.
Five experienced account managers with a strong track record in the equine sector have been appointed by Pfizer to build relationships with equine vet practices on a regional basis. They are:
- Mark Baker (south-east England)
- Laurie May (west-midlands, Cheshire, Wales)
- Penny McCann (East Anglia, east-midlands)
- Anna Cunningham (south-west, south Wales)
- Alexandra Cox (The North, Scotland)
Mr Lacey said: “Building our new team and combining the highly regarded products offered previously by both Fort Dodge and Pfizer has proved a stimulating process. We’ve also worked closely with many of our existing practice customers to look at how we can develop the service we provide to them.
“We’re now able to offer a product range which I believe is unrivalled in the market and a highly committed team of equine professionals who share a vision and passion for equine health. We’re looking forward to building our business with both existing and new customers in the months ahead.”